These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8653476)

  • 41. KS update.
    Notes Undergr; 1995; (no 29):4. PubMed ID: 11362282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin.
    Masood R; Husain SR; Rahman A; Gill P
    AIDS Res Hum Retroviruses; 1993 Aug; 9(8):741-6. PubMed ID: 8217343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.
    Grange C; Geninatti-Crich S; Esposito G; Alberti D; Tei L; Bussolati B; Aime S; Camussi G
    Cancer Res; 2010 Mar; 70(6):2180-90. PubMed ID: 20215497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.
    Sharpe M; Easthope SE; Keating GM; Lamb HM
    Drugs; 2002; 62(14):2089-126. PubMed ID: 12269857
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early approval for two lipid-based drugs.
    Baker R
    BETA; 1995 Dec; ():4. PubMed ID: 11363009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kaposi's sarcoma: DaunoXome approved.
    AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Paclitaxel for treating KS.
    Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liposomal doxorubicin.
    Linsky KF; Ignoffo RJ
    Cancer Pract; 1996; 4(5):288-90. PubMed ID: 9004577
    [No Abstract]   [Full Text] [Related]  

  • 49. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.
    Stewart S; Jablonowski H; Goebel FD; Arasteh K; Spittle M; Rios A; Aboulafia D; Galleshaw J; Dezube BJ
    J Clin Oncol; 1998 Feb; 16(2):683-91. PubMed ID: 9469358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of AIDS and its attendant malignancies.
    Volberding PA; Kaplan LD
    Prog Clin Biol Res; 1989; 288():459-70. PubMed ID: 2654959
    [No Abstract]   [Full Text] [Related]  

  • 52. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
    White RM
    AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
    [No Abstract]   [Full Text] [Related]  

  • 53. Liposomal doxorubicin.
    Wilkinson K
    Clin J Oncol Nurs; 2002; 6(1):59-61. PubMed ID: 11842492
    [No Abstract]   [Full Text] [Related]  

  • 54. Kaposi's sarcoma: DOX-SL approval recommended.
    AIDS Treat News; 1995 Feb; (no 217):8. PubMed ID: 11362308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases.
    Cabriales S; Bresnahan J; Testa D; Espina BM; Scadden DT; Ross M; Gill PS
    Oncol Nurs Forum; 1998; 25(1):67-70. PubMed ID: 9460774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
    Northfelt DW; Dezube BJ; Thommes JA; Miller BJ; Fischl MA; Friedman-Kien A; Kaplan LD; Du Mond C; Mamelok RD; Henry DH
    J Clin Oncol; 1998 Jul; 16(7):2445-51. PubMed ID: 9667262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma.
    Poizot-Martin I; Giovannini M; Rosello R; Viallat JR; Sauniere JF; Dalmas AM; Genre D; Dhiver C; Gastaut JA
    J Clin Oncol; 1994 Mar; 12(3):645. PubMed ID: 8120565
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of Kaposi's sarcoma with liposomal doxorubicin.
    Bergin C; O'Leary A; McCreary C; Sabra K; Mulcahy F
    Am J Health Syst Pharm; 1995 Sep; 52(18):2001-4. PubMed ID: 8528867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions.
    Hernández-Morales DE; Hernández-Zaccaro AE
    Eur J Cancer Care (Engl); 2005 Jul; 14(3):264-6. PubMed ID: 15952971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Liposomal doxorubicin and palmoplantar erythrodysesthesia].
    Tomb R; Stephan F; Halaby G
    Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.